Mouse Nuak2 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8BZN4 |
---|---|
Clone Names | 110316306 |
Gene ID | 74137 |
---|---|
Other Names | NUAK family SNF1-like kinase 2, Omphalocele kinase 2, Nuak2 {ECO:0000312|MGI:MGI:1921387}, Omphk2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | Nuak2 {ECO:0000312|MGI:MGI:1921387} |
---|---|
Synonyms | Omphk2 |
Function | Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Phosphorylates LATS1 and LATS2. Plays a key role in neural tube closure during embryonic development through LATS2 phosphorylation and regulation of the nuclear localization of YAP1 a critical downstream regulatory target in the Hippo signaling pathway. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells (By similarity).
References
Koh, H.J., et al. Proc. Natl. Acad. Sci. U.S.A. 107(35):15541-15546(2010)Ichinoseki-Sekine, N., et al. Am. J. Physiol. Endocrinol. Metab. 296 (5), E1013-E1021 (2009) :Tsuchihara, K., et al. Cancer Sci. 99(4):677-682(2008)Hirano, M., et al. Dev. Dyn. 235(8):2229-2237(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.